personalized combination of cancer cell vaccination and “killer” T cell treatment. This treatment has demonstrated the potential to effectively treat numerous cancers without many of the

undesirable side effects associated with radiation and chemotherapy. A key distinction between TVAX and other cancer immunotherapy companies is that TVI uses its patented approach to combine both cancer vaccination and activated “killer” T cell treatment. While each of these separate approaches has demonstrated therapeutic potential, neither has demonstrated the efficacy to be a viable standalone treatment.